ABMR	antibody-mediated rejection
Abs	antibodies
AIH	autoimmune hepatitis
AMA	anti-mitochondrial antibodies
ANCA	anti-neutrophil cytoplasmic autoantibodies
anti-HBc Abs	anti-hepatitis B core antibodies
CNI	calcineurin inhibitors
CR	clinical recurrence
DAA	direct-acting antivirals
DM	diabetes mellitus
dnDSA	de novo donor specific anti-HLA antibodies
DSA	donor specific anti-HLA antibodies
FGN	fibrillary glomerulonephritis
FSGS	focal segmental glomerulosclerosis
g-DSA	intra-graft DSA
GAD65	glutamic acid decarboxylase 65
GBM	anti-glomerular basement membrane
GdIgA1	galactose-deficient IgA1
HBeAg	hepatitis B e antigen
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
HLA	human leukocyte antigen
IAA	insulin autoantibody
IA-2	insulinoma-associated protein-2
ICA	islet cell antibodies
IFTA	interstitial fibrosis and tubular atrophy
IgAN	IgA nephropathy
IVIG	intravenous immunoglobulin therapy
mCR	mild-to-moderate clinical recurrence
MELD	model for end-stage liver disease
MN	membranous nephropathy
MPGN	membranoproliferative glomerulonephritis
mTOR	mammalian target of rapamycin
PBC	primary biliary cholangitis
PLA2R	anti-phospholipase A2 receptor antibodies
PR	pathological recurrence
PSC	primary sclerosing cholangitis
RPGN	rapidly progressive glomerulonephritis
s-DSA	serum DSA
sCR	severe clinical recurrence
SLE	systemic lupus erythematosus
suPAR	soluble urokinase type plasminogen activator receptor
SVR	sustained virological response
TCMR	T cell-mediated rejection
THSD7A	thrombospondin type-1 domain-containing 7A antibodies
UDCA	ursodeoxycholic acid
ZnT8	zinc transporter 8
αIgA	anti-GdIgA1 IgG